Literature DB >> 8547046

Topical isotretinoin in Darier's disease.

S M Burge1, P K Buxton.   

Abstract

Topical 0.05% isotretinoin (Isotrex gel) was used to treat a test patch of skin in 11 patients with Darier's disease. Hyperkeratosis and papules improved in six patients after treatment for 3 months. Erythema, burning and irritation were common adverse effects, and these were severe in three patients, one of whom stopped treatment. Patients with mild Darier's disease may find topical isotretinoin helpful, but it is likely that most patients with widespread disease will require treatment with systemic retinoids.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8547046     DOI: 10.1111/j.1365-2133.1995.tb06927.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  6 in total

Review 1.  Darier's disease: a calcium-signaling perspective.

Authors:  B Pani; B B Singh
Journal:  Cell Mol Life Sci       Date:  2008-01       Impact factor: 9.261

2.  [Segmental Darier disease : treatment with pulsed dye laser].

Authors:  L Schmitt; S Roos; C Raulin; S Karsai
Journal:  Hautarzt       Date:  2009-12       Impact factor: 0.751

Review 3.  Management of Darier disease: A review of the literature and update.

Authors:  Roger N Haber; Nicole G Dib
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Jan-Feb       Impact factor: 2.545

Review 4.  Darier Disease - A Multi-organ Condition?

Authors:  Etty Bachar-Wikström; Jakob D Wikström
Journal:  Acta Derm Venereol       Date:  2021-04-15       Impact factor: 3.875

5.  Efficacy of the Radiotherapy on Darier's Disease: An Indirect Evidence.

Authors:  Ala Podgornii; Patrizia Ciammella; Dafne Ramundo; Cinzia Iotti
Journal:  Case Rep Dermatol Med       Date:  2013-09-03

Review 6.  Therapeutic Options for the Treatment of Darier's Disease: A Comprehensive Review of the Literature.

Authors:  Nardin Hanna; Megan Lam; Patrick Fleming; Charles W Lynde
Journal:  J Cutan Med Surg       Date:  2021-11-28       Impact factor: 2.854

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.